CDY 1.43% 7.1¢ cellmid limited

News: CDY Cellmid Posts H1 Revenue Of $3.6 Mln, page-8

  1. 1,439 Posts.
    lightbulb Created with Sketch. 49
    My original decision to invest in Cellmid was because of their large pipeline of patents for midkine. Since that time we have shifted focus to the consumer health business which is proving to be a successful strategy. I would still like to have some exposure to the clinical programs but do understand that it is high risk.
 
watchlist Created with Sketch. Add CDY (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.